Lack of association between matrix metalloproteinase-1 (MMP-1) promoter polymorphism and risk of renal cell carcinoma

Autor(es)

Michelly F. Piccoli ^[1] ; Marcia Figueira ^[2] ; Cassio Andreoni ^[3] ; Julio T. Marumo ^[4] ; Nestor Schor ^[5] ; Maria H. Bellini

Afiliação do(s) autor(es)

^[1] Federal University of Sao Paulo. Section of Nephrology - Brasil

^[2] Federal University of Sao Paulo. Section of Nephrology - Brasil

^[3] Federal University of Sao Paulo. Section of Urology - Brasil

^[4] Federal University of Sao Paulo. Institute of Energetic and Nuclear Research - Brasil

^[5] Federal University of Sao Paulo. Section of Nephrology - Brasil

• Tipo de documento: Artigo Científico
• Fonte: INTERNATIONAL BRAZ J UROL; v. 33, n. 5, p. 622-629, 2007-10-00.

Resumo

OBJECTIVE: Investigate the possible association of insertion/deletion (2G/G) polymorphism at nucleotide -1607 of the MMP-1 promoter with the development and progression of renal cancer MATERIALS AND METHODS: In this study, we genotyped 217 individuals, 99 patients with renal cell carcinoma (RCC) and 118 controls without cancer. DNA specimens were extracted from epithelial buccal cells and paraffin-embedded tissue of RCC patients and from epithelial buccal cells and blood cells of healthy controls RESULTS: The difference in frequency of 2G/2G genotype between controls (22.9%) and RCC patients (28.6%) was not statistically significant (p = 0.461). We also did not find correlation between 2G/2G and histological type of RCC. The comparison of genotype distribution and frequency of 2G allele in different populations showed a strong variability of 2G allele frequency among the different ethnic groups. This fact may influence on the collaboration of this 2G allele in RCC or others diseases CONCLUSION: Our data suggest that the matrix metalloproteinase-1 (MMP-1) promoter polymorphism may not play a significant role in renal cell carcinoma patients in Brazil. (AU)

• Processo FAPESP: 03/11779-7 - Implante de fibroblastos transduzidos com cDNA da endostatina murina para o tratamento antiangiogênico de carcinoma renal
• Beneficiário: Maria Helena Bellini Marumo
• Modalidade de apoio: Auxílio à Pesquisa - Regular